Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04835597 · ClinicalTrials.gov registry record
Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- 27
- Enrollment target
NCT04835597: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT04835597 is a clinical trial that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04835597 was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- 27 participants
- Enrollment target
Study Summary
This study assesses the performance status in stage I-III triple negative breast cancer patients who are receiving neoadjuvant chemotherapy. Information collected in this study may help doctors learn if movement and fitness trackers can be used to predict side effects in cancer patients receiving chemotherapy.
Interventions
- OTHER Electronic Health Record Review
- BEHAVIORAL Behavioral Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2024-08-21 |
Why NCT04835597 stopped before completion
NCT04835597 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Electronic Health Record Review is the first listed.
NCT04835597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04835597 about?
NCT04835597 is a clinical study titled "Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy". This study assesses the performance status in stage I-III triple negative breast cancer patients who are receiving neoadjuvant chemotherapy. Information collected in this study may help doctors learn if movement and fitness trackers can be used to predict side effects in cancer patients receiving ch...
What is the current status of trial NCT04835597?
This trial is currently terminated. The enrollment target is 27 participants. The study started on 2022-08-15. Estimated completion is 2024-08-21.
What interventions are being tested in trial NCT04835597?
The interventions under investigation include: Electronic Health Record Review (OTHER), Behavioral Assessment (BEHAVIORAL).
Who is sponsoring clinical trial NCT04835597?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI